A Clinical Study on Oncolytic Virus Injection (R130) for the Treatment of Relapsed/Refractory Advanced Solid Tumors
Conditions: Lung Cancer; Bronchial Cancer; Non Small Cell Lung Cancer; Small Cell Lung Cancer; Sarcoma; Colorectal Cancer; Gastric Cancer; Liver Cancer; Breast Cancer; Pancreatic Cancer; Head and Neck Cancer; Ovarian Cancer Intervention: Drug: Recombinant oncolytic herpes simplex virus type 1 (R130) Sponsors: Shanghai Yunying Medical Technology; The PLA Navy Anqing Hospital Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - June 2, 2023 Category: Research Source Type: clinical trials